Cardiology Department, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, China.
PLoS One. 2024 May 31;19(5):e0300500. doi: 10.1371/journal.pone.0300500. eCollection 2024.
The cardiac-brain connection has been identified as the basis for multiple cardio-cerebral diseases. However, effective therapeutic targets for these diseases are still limited. Therefore, this study aimed to identify pleiotropic and specific therapeutic targets for cardio-cerebral diseases using Mendelian randomization (MR) and colocalization analyses.
This study included two large protein quantitative trait loci studies with over 4,000 plasma proteins were included in the discovery and replication cohorts, respectively. We initially used MR to estimate the associations between protein and 20 cardio-cerebral diseases. Subsequently, Colocalization analysis was employed to enhance the credibility of the results. Protein target prioritization was based solely on including highly robust significant results from both the discovery and replication phases. Lastly, the Drug-Gene Interaction Database was utilized to investigate protein-gene-drug interactions further.
A total of 46 target proteins for cardio-cerebral diseases were identified as robust in the discovery and replication phases by MR, comprising 7 pleiotropic therapeutic proteins and 39 specific target proteins. Followed by colocalization analysis and prioritization of evidence grades for target protein, 6 of these protein-disease pairs have achieved the highly recommended level. For instance, the PILRA protein presents a pleiotropic effect on sick sinus syndrome and Alzheimer's disease, whereas GRN exerts specific effects on the latter. APOL3, LRP4, and F11, on the other hand, have specific effects on cardiomyopathy and ischemic stroke, respectively.
This study successfully identified important therapeutic targets for cardio-cerebral diseases, which benefits the development of preventive or therapeutic drugs.
心脏-大脑连接已被确定为多种心脑血管疾病的基础。然而,这些疾病的有效治疗靶点仍然有限。因此,本研究旨在使用孟德尔随机化(MR)和共定位分析来确定心脑血管疾病的多效性和特异性治疗靶点。
本研究纳入了两项大型蛋白质定量性状基因座研究,分别纳入了超过 4000 种血浆蛋白的发现和复制队列。我们最初使用 MR 估计蛋白与 20 种心脑血管疾病之间的关联。随后,进行共定位分析以提高结果的可信度。蛋白质靶标优先级仅基于发现和复制阶段均包含高度稳健的显著结果。最后,利用药物-基因相互作用数据库进一步研究蛋白质-基因-药物相互作用。
通过 MR 在发现和复制阶段共鉴定出 46 种心脑血管疾病的靶蛋白,其中包括 7 种多效性治疗蛋白和 39 种特异性靶蛋白。继共定位分析和证据等级对靶蛋白进行优先级排序后,这 6 个蛋白-疾病对达到了高度推荐的水平。例如,PILRA 蛋白对病态窦房结综合征和阿尔茨海默病具有多效性作用,而 GRN 对后者具有特异性作用。APOL3、LRP4 和 F11 则分别对心肌病和缺血性中风具有特异性作用。
本研究成功鉴定了心脑血管疾病的重要治疗靶点,有助于预防或治疗药物的开发。